Back to results
US 7,582,652 B2Granted
Kinase inhibitors
AssigneeEli Lilly and Company
InventorsRosanne Bonjouklian, Chafiq Hamdouchi, Chuan Shih, Alfonso De Dios, Miriam Filadelfa del Prado, Carlos Jaramillo Aguado, Pramila Kotiyan, Mary Margaret Mader, Sheila Pleite Selgas, Concepcion Sanchez-Martinez
Life of this patent
Estimating the term…
Abstract
The present invention provides kinase inhibitors of Formula I.
Claims7
A compound of Formula I:
- where:
- W is:
- X is N, or C—R1;
- R is C1-C7 alkyl, C3-C7 cycloalkyl, (C1-C7 alkylene)-(C3-C7 cycloalkyl), —SO2—(C1-C7 alkyl), or —SO2—NR5R6;
- R1 is hydrogen, amino, methyl, or —N═CH(NMe)2;
- R2 is phenyl optionally substituted with one or two substituents independently selected from halo;
- R3 is hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, or phenyl optionally substituted with one or two substituents independently selected from halo and trifluoromethyl;
- R4 is hydrogen or C1-C7 alkyl;
- R5 and R6 are independently selected from the group consisting of C1-C7 alkyl;
- or a pharmaceutically acceptable salt thereof.
7 more elements
A compound of Formula I′:
- where:
- R1 is 2,2-dimethylpropyl or 1,2,2-trimethylpropyl;
- R2′ is phenyl, 4-fluorophenyl, or 2,4-difluorophenyl;
- R3′ is tert-butyl, 2-chloro-6-fluorophenyl, 2-fluoro-6-trifluoromethylphenyl, 2,6-dichlorophenyl, or 2,6-difluorophenyl;
- or a pharmaceutically acceptable salt thereof.
2 more elements
A pharmaceutical formulation comprising a compound of Formula I:
- where:
- W is:
- X is N, or C—R1;
- R is C1-C7 alkyl, C3-C7 cycloalkyl, (C1-C7 alkylene)-(C3-C7 cycloalkyl), —SO2—(C1-C7 alkyl), or —SO2—NR5R6;
- R1 is hydrogen, amino, methyl, or —N═CH(NMe)2;
- R2 is phenyl optionally substituted with one or two substituents independently selected from halo;
- R3 is hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, or phenyl optionally substituted with one or two substituents independently selected from halo and trifluoromethyl;
- R4 is hydrogen or C1-C7 alkyl;
- R5 and R6 are independently selected from the group consisting of C1-C7 alkyl;
- or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, diluent or excipient.
7 more elements
A method of inhibiting p-38 kinase in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I:
- where:
- W is:
- X is N, or C—R1;
- R is C1-C7 alkyl, C3-C7 cycloalkyl, (C1-C7 alkylene)-(C3-C7 cycloalkyl), —SO2—(C1-C7 alkyl), or —SO2—NR5R6;
- R1 is hydrogen, amino, methyl, or —N═CH(NMe)2;
- R2 is phenyl optionally substituted with one or two substituents independently selected from halo;
- R3 is hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, or phenyl optionally substituted with one or two substituents independently selected from halo and trifluoromethyl;
- R4 is hydrogen or C1-C7 alkyl;
- R5 and R6 are independently selected from the group consisting of C1-C7 alkyl;
- or a pharmaceutically acceptable salt thereof.
7 more elements
Dependencies are inferred from the claim text.